Abstract: Compositions containing a high concentration of the full repertoire of immunoglobulins, including IgA, IgM and IgG, are used to combat infections from microorganisms and viruses at a wound, surgical, or burn site, or normal tissue times of risk of infection. The compositions can contain elevated antibody titers for several specific pathogens including S. aureus, Coagulase Negative Staphylococci Enterococci, S. epidermidis, P. aeruginosa, E. coli, and Enterobacter spp., etc. The compositions are applied directly to a wound or burn site as an ointment, creme, fluid, spray, or the like, prior to viral or bacterial attachment or biofilm formation such that adhesion of the pathogens is inhibited and the pathogens closest to the wound or burn site will be pre-opsonized for phagocytic killing prior to toxin release.

Abstract: Disclosed are a bispecific hybrid MoAb having specificity for both an activated platelet and a substance having thrombolytic activity, and a thrombolytic agent comprising the above bispecific MoAb and a substance having thrombolytic activity immunologically bound thereto, whereby efficient, rapid thrombolysis is possible.

Abstract: In a method of treating ketosis in an animal during pregnancy or lactation, such as toxaemia of pregnancy or fat cow syndrome, the amount or activity of somatotropin in the blood is increased while administering glucose or a glucose precursor to the affected animal.

Abstract: Methods for the use of a fibrin-specific antibody for in vivo inhibition of thrombus formation. Pharmaceutical compositions, as well as kits, for use in such methods are also provided.

Abstract: Disclosed are a monoclonal antibody having affinity for PACAP, a partial peptide thereof, a precursor thereof or VIP; a hybridoma cell which produces the above monoclonal antibody; and an immunoassay for assaying PACAP by a competitive method or a sandwich method using the above antibody, whereby PACAP can be specifically detected with high sensitivity.

Abstract: The present invention provides novel hybridoma cell lines which produce monoclonal antibodies (MoAbs) that bind epitopes found on lipopolysaccharide most commonly associated with the endotoxin core of gram negative bacteria and exhibit broad cross-reactivity with gram negative bacteria of different genera and effectively neutralize endotoxin. At least one of the MoAbs disclosed (XMMEN-J5D) binds an epitope also found on gram positive bacteria. The hybridomas are produced by fusing an immortal cell, a cell having the ability to replicate indefinitely in myeloma cell culture, and an effector immune cell following immunization of the immune cell host with a preparation of a gram negative bacteria. While several individual hybridoma cell lines producing monoclonal antibodies to lipopolysaccharide are described, the present invention adds to the state of the art an entire family of hybridomas producing monoclonal antibodies to lipopolysaccharide-associated epitopes.

Abstract: This invention relates to a method of cancer therapy for treating human patients with resectable solid tumors to inhibit recurrence and formation of metastases, comprising surgically removing tumor tissue from a human cancer patient, treating the tumor tissue to obtain tumor cells, irradiating the tumor cells to be viable but non-tumorigenic, preparing a vaccine comprising about 10.sup.7 viable but non-tumorigenic tumor cells per dose and injecting the vaccine intradermally into the human patient after the patient's immune system has recovered from surgery.

Abstract: A peptide-specific monoclonal antibody derived from an immunogenic peptide from the extracellular hydrophilic region of the human C5 a receptor (C5aR) is useful for blocking C5a from binding to C5aR.

Abstract: A monoclonal antibody is produced from a cloned hybridoma, and the monoclonal antibody combines specifically with basic fibroblast growth factor (bFGF). Therefore, the monoclonal antibody can be advantageously used for assay reagents on bFGF or for purification of bFGF.

Abstract: The present invention relates to anti-idiotypic antibodies directed against Neisseria gonorrhoeae. This invention also relates to methods and compositions using such anti-idiotypic antibodies for the prophylaxis, treatment and diagnosis of gonorrheal infections.

Abstract: This invention relates to monoclonal antibody 88BV59 produced by B-cell lines derived from B-cells of cancer patients actively immunized with autologous tumor antigen. These monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.

Abstract: An antibody that immunoreacts with a ligand-induced binding site (LIBS) on GPIIIa, and particularly, a LIBS induced in a platelet-associated GPIIb-IIIa/fibrinogen complex is disclosed. Further disclosed are diagnostic systems and methods for assaying LIBS-containing platelets in a vascular fluid sample using the antibodies of the invention.

Abstract: Potent neutralizing monoclonal antibodies to the human .alpha. PDGF receptor (.alpha. PDGFR) and fragments thereof are described. These monoclonal antibodies specifically bind to an epitope on .alpha. PDGFR, inhibits PDGF binding with PDGF, antagonizes PDGF, and does not bind .beta. PDGFR receptor. A hybridoma cell line producing such a monoclonal antibody, methods of in vivo imaging of a pathological conditions and methods of inhibiting the growth of a neoplasia expressing .alpha. PDGFR, which use these monoclonal antibodies are also described. In vitro assays for detecting the presence of .alpha. PDGFR and for evaluating the binding affinity of a test compound are also described.

Abstract: Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods of producing these polypeptide chains using recombinant DNA technology; (5) antibodies specific for these novel polypeptide chains; (6) osteogenic devices comprising these recombinantly produced proteins in association with an appropriate carrier matrix; and (7) methods of using the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.

Abstract: An antibody which specifically binds with a human prohibitin or a partial structural fragment thereof can be used as a diagnostic agent in the detection of cancer. The human prohibitin has the structure illustrated in SEQ ID NO:1.

Abstract: The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.

Abstract: A chimeric molecule that contains a fibrin-binding portion of an antibody covalently linked to an inhibitor of thrombin, which molecule is administered to inhibit thrombus formation and growth.

Abstract: Apotransferrin bound to zinc or copper is administered to a patient who has endotoxins present in the patient's bloodstream. The apotransferrin improves the elimination of endotoxins from the bloodstream.

Abstract: cDNAs encoding a class of receptors, including the IL-8 type B receptor, have been identified in human tissue. Recombinantly produced IL-8 type B receptor is used in the preparation and purification of antibodies capable of binding to the receptor, and in diagnostic assays. The antibodies are advantageously used in the prevention and treatment of inflammatory conditions.

Abstract: The present invention provides a hybrid cell line producing monoclonal antibody to an acidic fibroblast growth factor (aFGF) protein. The hybridoma is established by fusing spleen cells from immunized mice with myeloma cells. The hybridomas are cultured as clones, and antibodies obtained from the individual clones are tested for their specificity for aFGF protein. Antibodies can be obtained from the culture growth medium or from ascitic fluid of mice bearing the hybridoma tumor. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.